- Home
- INBS vs APRE Comparison
INBS vs APRE Comparison
Compare INBS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBS
- APRE
- Stock Information
- Founded
- INBS 2016
- APRE 2006
- Country
- INBS United States
- APRE United States
- Employees
- INBS N/A
- APRE N/A
- Industry
- INBS Medical Specialities
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INBS Health Care
- APRE Health Care
- Exchange
- INBS Nasdaq
- APRE Nasdaq
- Market Cap
- INBS 11.7M
- APRE 10.0M
- IPO Year
- INBS N/A
- APRE 2019
- Fundamental
- Price
- INBS $1.72
- APRE $1.86
- Analyst Decision
- INBS
- APRE Strong Buy
- Analyst Count
- INBS 0
- APRE 2
- Target Price
- INBS N/A
- APRE $15.50
- AVG Volume (30 Days)
- INBS 253.7K
- APRE 76.8K
- Earning Date
- INBS 09-18-2025
- APRE 08-11-2025
- Dividend Yield
- INBS N/A
- APRE N/A
- EPS Growth
- INBS N/A
- APRE N/A
- EPS
- INBS N/A
- APRE N/A
- Revenue
- INBS $2,936,472.00
- APRE $1,284,475.00
- Revenue This Year
- INBS $280.88
- APRE N/A
- Revenue Next Year
- INBS $126.26
- APRE N/A
- P/E Ratio
- INBS N/A
- APRE N/A
- Revenue Growth
- INBS 3.87
- APRE 33.27
- 52 Week Low
- INBS $1.00
- APRE $1.41
- 52 Week High
- INBS $3.00
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- INBS 48.37
- APRE 59.75
- Support Level
- INBS $1.76
- APRE $1.89
- Resistance Level
- INBS $2.27
- APRE $2.22
- Average True Range (ATR)
- INBS 0.18
- APRE 0.16
- MACD
- INBS -0.01
- APRE 0.03
- Stochastic Oscillator
- INBS 25.56
- APRE 59.27
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.